Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (noted as TALPHERA, INC. in metadata) on July 18, 2017. The report discloses the appointment of a new Chief Financial Officer effective August 16, 2017.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $400,000 annually.
- Target Bonus: 30% of base salary (pro-rated for 2017).
- Equity Grant: Option to purchase 220,000 shares of common stock.
- Exercise Price: Closing sales price on the start date (August 16, 2017).
- Vesting Schedule: 25% on the first anniversary; remaining 75% vesting monthly over the subsequent 36 months.
Material Changes
The primary material change is the appointment of Raffi M. Asadorian as Chief Financial Officer. Prior to this role, Mr. Asadorian served as CFO of Amyris, Inc. (2015-2017) and Group CFO of Unilabs (2009-2014). The filing does not report material changes to financial performance compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It notes that the employment is on an "at-will" basis and that bonus payments are contingent on corporate and individual performance objectives determined by the Compensation Committee. The equity grant is subject to continuous service.
Investor Verification Checklist
- Verify the exact closing stock price on August 16, 2017, to determine the exercise price of the 220,000 share option grant.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics tied to the bonus plan.
- Confirm the pro-rated bonus calculation for the partial year of 2017.
- Check subsequent filings for any changes to the vesting schedule or employment status.